Systemic treatments for metastatic cutaneous melanoma-Reference-Cited by-同舟云学术

Systemic treatments for metastatic cutaneous melanoma

Published:2014-05-29 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Pasquali Sandro¹,Kefford Richard²,Chiarion Sileni Vanna³,Nitti Donato⁴,Rossi Carlo Riccardo⁵,Pilati Pierluigi⁶,Mocellin Simone⁷⁸

Affiliation:

1. Veneto Institute of Oncology - IRCCS; Surgical Oncology Unit; Via Gattamelata 64 Padova Italy 35128

2. The University of Sydney; Discipline of Medicine; Clinical Sciences Block, Westmead Hospital Westmead Australia 2145

3. Veneto Region Oncology Research Institute; Medical Oncology Unit 2; Via Gattamelata 64 Padova Italy 35128

4. University of Padova; Clinica Chirurgica II; Via Giustiniani 2 Padova Italy 35128

5. Veneto Institute of Oncology; Melanoma and Sarcomas Unit; Via Gattamelata 64 Padova Italy 35128

6. University of Padova; Meta-Analysis Unit, Department of Surgery, Oncology and Gastroenterology; via Giustiniani 2 Padova Italy 35128

7. University of Padova; Dept. Surgery Oncology and Gastroenterology; Via Giustiniani 2 Padova Veneto Italy 35128

8. IOV-IRCCS; Istituto Oncologico Veneto; Padova Italy 35100

Publisher

Wiley

Subject

Pharmacology (medical)

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/14651858.CD011123/fullpdf

Reference70 articles.

1. Calculating the number needed to treat for trials where the outcome is time to an event;Altman;BMJ,1999

2. Targeting BRAF for patients with melanoma;Arkenau;British Journal of Cancer,2011

3. Australian Cancer Network Melanoma Guidelines Revision Working Party Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand ( CP111) Wellington 2008

4. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma;Bajetta;Annals of Oncology,2006

5. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system;Balch;Journal of Clinical Oncology,2001

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: The power of immunotherapy in advanced cutaneous squamous cell carcinoma;Frontiers in Oncology;2023-01-04

2. Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience;Biomedicines;2022-10-10

3. Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients;Cancers;2022-08-23

4. The Influence of c-Kit and NRAS Mutation on Patients’ Survival in Metastatic Melanoma Receiving Immune Checkpoint Inhibitors and Chemotherapy;Dermato;2022-06-01

5. An Easily Expandable Multi-Drug LC-MS Assay for the Simultaneous Quantification of 57 Oral Antitumor Drugs in Human Plasma;Cancers;2021-12-16